



(43) International Publication Date
27 December 2012 (27.12.2012)

(10) International Publication Number
WO 2012/177962 A1

(51) International Patent Classification:
C07D 457/00 (2006.01)

(21) International Application Number:
PCT/US2012/043677

(22) International Filing Date:
22 June 2012 (22.06.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/571,299 23 June 2011 (23.06.2011) US

(71) Applicant (for all designated States except US): **MAP PHARMACEUTICALS, INC.** [US/US]; 2400 Bayshore Parkway, Suite 200, Mountain View, CA 94043 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COOK, Robert, O.** [GB/US]; 42 Scott Drive, Hillsborough, NJ 08844 (US). **ZHANG, Jian** [CN/US]; 2400 Bayshore Parkway, Suite 200, Mountain View, CA 94043 (US). **ARMER, Thomas, A.** [US/US]; 2400 Bayshore Parkway, Suite 200, Mountain View, CA 94043 (US).

(74) Agent: **CHENG, Jennifer, C.**; Map Pharmaceuticals, Inc., 2400 Bayshore Parkway, Suite 200, Mountain View, CA 94043 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL FLUOROERGOLINE ANALOGS

(57) Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT_{1D} and/or the 5-HT_{1B} receptor, without agonizing the 5-HT_{2B} receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha_{2A} and/or the alpha_{2B} receptors using the compounds and compositions disclosed herein.



WO 2012/177962 A1